Auricular and Periauricular Skin Cancers

  • Blair Barton
  • Brian Moore


Cutaneous malignancy is the most common cancer worldwide and has been estimated to account for approximately one million new cases each year in the United States alone. Basal cell carcinoma makes up the overwhelming majority of these cases, accounting for 80%. The remainder is made up by squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Approximately 80–90% of these malignancies appear on sun-exposed areas of the head and neck, and the auricle is estimated to be involved at an incidence of 5–10%.

Historically, cutaneous tumors of the auricle were thought to have similar malignant potential as other subsites. However, squamous cell carcinoma of the auricle has been shown to have a greater metastatic potential than other subsites, potentially related to its different histologic behavior with sun exposure compared to the rest of the body. Auricular melanoma was originally associated with a poorer prognosis; however, recent literature shows that survival outcomes of melanoma of the auricle are similar to those at other subsites of the body.

Treatment of advanced auricular lesions should involve a multidisciplinary tumor board approach. Due to its prominent location, the functionality and cosmetic appearance of the auricle require special attention during multidisciplinary management.


Auricle Ear Periauricular Squamous cell carcinoma Basal cell carcinoma Merkel cell carcinoma Melanoma Parotidectomy Sentinel lymph node biopsy Chemotherapy Radiation therapy 


  1. 1.
    American Cancer Society. 2010, cited 2016 June. Available from
  2. 2.
    Porceddu SV, Veness MJ, Guminski A. Nonmelanoma cutaneous head and neck cancer and merkel cell carcinoma: current concepts, advances, and controversies. J Clin Oncol. 2015;33(29):3338–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146:283–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(3):975–83.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Basal cell and squamous cell skin cancers.Google Scholar
  6. 6.
    Clark RR, Soutar DS. Lymph node metastases from auricular squamous cell carcinoma. A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2008;61(10):1140–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Ahmad I, Das Gupta AR. Epidemiology of basal cell carcinoma and squamous cell carcinoma of the pinna. J Laryngol Otol. 2001;115(2):85–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous-cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol. 1992;26(6):976–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Mondin V, Rinaldo A, Shaha AR, et al. Malignant melanoma of the auricle. Acta Otolaryngol. 2005;125(11):1140–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Toia F, Garbo G, Tripoli M, et al. A systematic review on external ear melanoma. J Plast Reconstr Aesthet Surg. 2015;68(7):883–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Lachiewicz AM, Berwick M, Wiggins CL, et al. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol. 2008;144(4):515–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Ravin AG, Pickett N, Johnson JL, et al. Melanoma of the ear: treatment and survival probabilities based on 199 patients. Ann Plast Surg. 2006;57(1):70–6.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Dubas LE, Ingraffea A. Nonmelanoma skin cancer. Facial Plast Surg Clin North Am. 2013;21(1):43–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Rodgers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151(10):1081–8.CrossRefGoogle Scholar
  15. 15.
    Jones TS, Jones EL, Gao D, et al. Management of external ear melanoma: the same of something different? Am J Surg. 2013;206(3):307–13.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Lee D, Nash M, Har-El G. Regional spread of auricular and periauricular cutaneous malignancies. Laryngoscope. 1996;106(8):998–1001.PubMedCrossRefGoogle Scholar
  17. 17.
    Gurudutt VV, Genden EM. Cutaneous squamous cell carcinoma of the head and neck. J Skin Cancer. 2011;2011:502723.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    National Cancer Institute. SEER Stat Fact Sheets: Melanoma of the Skin. Cited 2016 June. Available from
  19. 19.
    Golger A, Young DS, Ghazarian D, et al. Epidemiological features and prognostic factors of cutaneous head and neck melanoma. Arch Otolaryngol Head Neck Surg. 2007;133(5):442–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Kolk A, Wolff KD, Kesting M, et al. Melanotic and non-melanotic malignancies of the face and external ear – a review of current treatment concepts and future options. Cancer Treat Rev. 2014;40(7):819–37.PubMedCrossRefGoogle Scholar
  21. 21.
    Danial C, Lingala B, Balise R, et al. Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. Br J Dermatol. 2013;169(3):255–61.CrossRefGoogle Scholar
  22. 22.
    Mydlardz WK, Weber RS, Kupferman ME. Cutaneous malignancy of the head and neck. Surg Oncol Clin N Am. 2015;24(3):593–613.CrossRefGoogle Scholar
  23. 23.
    Saini AT, Miles BA. Merkel cell carcinoma of the head and neck: pathogenesis, current and emerging treatment options. Onco Targets Ther. 2015;8:2157–67.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Chen MM, Roman SA, Sosa JA, et al. The role of adjuvant therapy in the management of head and neck merkel cell carcinoma. JAMA Otolaryngol Head Neck Surg 2015;141(2):137–41.CrossRefGoogle Scholar
  25. 25.
    Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Gandhi SA, Kampp J. Skin cancer epidemiology, detection, and management. Med Clin N Am. 2015;99(6):1323–35.PubMedCrossRefGoogle Scholar
  27. 27.
    Merlino G, Herlyn M, Fisher DE, et al. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016;29(4):404–16.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16(6):345–58.PubMedCrossRefGoogle Scholar
  29. 29.
    IARC. Exposure to Artificial UV Radiation and Skin Cancer. Lyon, France:IARC Working Group on Risk of Skin Cancer and Exposure to Artificial Ultraviolet Light, International Agency for Research on Cancer, World Health Organization; 2005. [Online]. Available from
  30. 30.
    Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–79.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Chockalingam R, Downing C, Tyring SK. Cutaneous squamous cell carcinomas in organ transplant recipients. J Clin Med. 2015;4(6):1229–39.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Walter A, Barysch MJ, Behnke S. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res. 2010;16(14):3562–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Southwell KE, Chaplin JM, Eisenberg RL, et al. Effect of immunocompromise on metastatic cutaneous squamous cell carcinoma in the parotid and neck. Head Neck. 2006;28(3):244–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management. Part I: Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):253–61.PubMedCrossRefGoogle Scholar
  35. 35.
    Song SS, Goldenberg A, Ortiz A, et al. Nonmelanoma skin cancer with aggressive subclinical extension in immunosuppressed patients. JAMA Dermatol. 2016;152(6):683–90.PubMedCrossRefGoogle Scholar
  36. 36.
    Ducroux E, Boillot O, Ocampo MA, et al. Skin cancers after liver transplantation: retrospective single-center study on 371 recipients. Transplantation. 2014;98(3):335–40.PubMedCrossRefGoogle Scholar
  37. 37.
    Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol. 2002;138(8):1043–51.PubMedCrossRefGoogle Scholar
  38. 38.
    Jaju PD, Batra RS, Kelley LC. Familial skin cancer syndromes: increased risk of nonmelanotic skin cancers and extracutaneous tumors. J Am Acad Dermatol. 2016;74(3):437–51.PubMedCrossRefGoogle Scholar
  39. 39.
    Ransohoff KJ, Jaju PD, Tang JY, et al. Familial skin cancer syndromes: increased melanoma risk. J Am Acad Dermatol. 2016;74(3):423–34.PubMedCrossRefGoogle Scholar
  40. 40.
    Sajic D, Archibald J, Murray C. Surface anatomy of the ear. J Cutan Med Surg. 2014;18(2):137–40.PubMedCrossRefGoogle Scholar
  41. 41.
    Osborne RF, Shaw T, Zandifar H, et al. Elective parotidectomy in the management of advanced auricular malignancies. Laryngoscope. 2008;118(12):2139–45.PubMedCrossRefGoogle Scholar
  42. 42.
    Sand M, Sand D, Brors D, et al. Cutaneous lesions of the external ear. Head Face Med. 2008;4:2.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Thom JJ, Moore EJ, Price DL, et al. The role of total parotidectomy for metastatic cutaneous squamous cell carcinoma and malignant melanoma. JAMA Otolaryngol Head Neck Surg. 2014;140(6):548–54.PubMedCrossRefGoogle Scholar
  44. 44.
    Brantsh KD, Meisner C, Schonfish B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713–20.CrossRefGoogle Scholar
  45. 45.
    Butler TD, Matin RN, Affleck AG, et al. Trends in dermoscopy use in the UK: results from surveys in 2003 and 2012. Dermatol Pract Concept. 2015;5(2):29–38.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Netterville JL, Sinard RJ, Bryant GL, et al. Delayed regional metastasis from midfacial squamous carcinomas. Head Neck. 1998;20(4):328–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Mendenhall WM, Amdur RJ, Williams LS, et al. Carcinoma of the skin of the head and neck with perineural invasion. Head Neck. 2002;24(1):78–83.PubMedCrossRefGoogle Scholar
  48. 48.
    Warren TA, Nagle CM, Bowman J, et al. The natural history and treatment outcomes of perineural spread of malignancy within the head and neck. J Neurol Surg B Skull Base. 2016;77(2):107–12.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Pan WR, le Roux CM, Levy SM, et al. Lymphatic drainage of the external ear. Head Neck. 2011;33(1):60–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989–2007.PubMedCrossRefGoogle Scholar
  51. 51.
    Zager JS, Hochwald SN, Marzban SS, et al. Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. J Am Coll Surg. 2011;212(4):454–60.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Scolyer RA, Judge MJ, Evans A, et al. Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol. 2013;37(12):1797–814.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Eisenmenger LB, Wiggins RH. Imaging of head and neck lymph nodes. Radiol Clin N Am. 2015;53(1):115–32.PubMedCrossRefGoogle Scholar
  54. 54.
    Duncan JR, Carr D, Kaffenberger BH. The utility of positron emission tomography with and without computed tomography in patients with nonmelanoma skin cancer. J Am Acad Dermatol. 2016;75(1):186–96.PubMedCrossRefGoogle Scholar
  55. 55.
    Kumar R, Alavi A. Clinical applications of fluorodeoxyglucose – positron emission tomography in the management of malignant melanoma. Curr Opin Oncol. 2005;17(2):154–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Siva S, Byrne K, Seel M, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. J Nucl Med. 2013;54(8):1223–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Byrne K, Siva S, Chait L, et al. 15-year experience of 18F-FDG PET imaging in response assessment and restaging after definitive treatment of Merkel cell carcinoma. J Nucl Med. 2015;56(9):1328–33.PubMedCrossRefGoogle Scholar
  58. 58.
    Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64(6):1051–9.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Chu VH, Tetzladd MT, Torres-Cabala CA, et al. Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. Biomed Res Int. 2013;2013:898719.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Alex JC. The application of sentinel node radiolocalization to solid tumors of the head and neck: a 10-year experience. Laryngoscope. 2004;114(1):2–19.PubMedCrossRefGoogle Scholar
  61. 61.
    Caldarella A, Fancelli L, Manneschi G, et al. How staging of thin melanoma is changes after introduction of TMN 7th edition: a population-based analysis. J Cancer Res Clin Oncol. 2016;142(1):73–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Smithers BM, Hughes MC, Beesley VL, et al. Prospective study of patterns of surgical management in adults with primary cutaneous melanoma at high risk spread, in Queensland, Australia. J Surg Oncol. 2015;112(4):359–65.PubMedCrossRefGoogle Scholar
  63. 63.
    Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Chren MM, Linos E, Torres JS, et al. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013;133(5):1188–96.PubMedCrossRefGoogle Scholar
  65. 65.
    McGillis ST, Fein H. Topical treatment strategies for non-melanoma skin cancer and precursor lesions. Semin Cutan Med Surg. 2004;23(3):174–83.PubMedCrossRefGoogle Scholar
  66. 66.
    Erickson C, Miller SJ. Treatment options in melanoma in situ: topical and radiation therapy, excision, and Mohs surgery. Int J Dermatol. 2010;49(5):482–91.PubMedCrossRefGoogle Scholar
  67. 67.
    Ermertcan AT, Hellings PW, Cingi X. Nonmelanoma skin cancer of the head and neck, nonsurgical treatment. Facial Plast Surg Clin North Am. 2012;20(4):445–54.PubMedCrossRefGoogle Scholar
  68. 68.
    Niparko JK, Swanson NA, Baker SR, et al. Local control of auricular, periauricular and external canal cutaneous malignancies with Mohs surgery. Laryngoscope. 1990;100(10 Pt 1):1047–51.PubMedCrossRefGoogle Scholar
  69. 69.
    Gupta A, Veness M, De’Ambrosis B, et al. Management of squamous cell and basal cell carcinomas of the head and neck with perineural invasion. Australas J Dermatol. 2016;57(1):3–13.PubMedCrossRefGoogle Scholar
  70. 70.
    Baddour HM, Magliocca KR, Chen AY. The importance of margins in head and neck cancer. J Surg Oncol. 2016;113(3):248–55.PubMedCrossRefGoogle Scholar
  71. 71.
    Craig ES, Nagarajan P, Lee ES, et al. The perichondrium in auricular melanomas: implications for surgical management. Otolaryngol Head Neck Surg. 2013;148(3):431–5.PubMedCrossRefGoogle Scholar
  72. 72.
    McCarty MA, Lentsch EJ, Cerrati EW, et al. Melanoma of the ear: results of a cartilage-sparing approach to resection. Eur Arch Otorhinolaryngol. 2013;270(11):2963–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Jahn V, Breuninger H, Garbe C, et al. Melanoma of the ear: prognostic factors and surgical strategies. Br J Dermatol. 2006;154(2):310–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Yenidunya MO. Surgical treatment of auricular malignancies when the anterior or posterior skin is intact. J Craniofac Surg. 2013;24(2):350–3.PubMedCrossRefGoogle Scholar
  75. 75.
    Mazzoni A, Zanoletti E, Marioni G, et al. En bloc temporal bone resections in squamous cell carcinoma of the ear. Technique, principles, and limits. Acta Otolaryngol. 2016;135(6):425–32.CrossRefGoogle Scholar
  76. 76.
    Kahn MK, Kahn N, Almasan A, et al. Future of radiation therapy for malignant melanoma an era of newer, more effective biological agents. Onco Tragets Ther. 2011;4:137–48.CrossRefGoogle Scholar
  77. 77.
    Mendenhall WM, Amdur RJ, Hinerman RW, et al. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009;119(10):1994–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Clark RR, Soutar DS, Hunter KD. A retrospective analysis of histological prognostic factors for the development of lymph node metastases from auricular squamous cell carcinoma. Histopathology. 2010;57(1):138–46.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Kadakia S, Ducic Y, Marra D, et al. The role of elective superficial parotidectomy in the treatment of temporal region squamous cell carcinoma. Oral Maxillofac Surg. 2016;20(2):143–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Michl C, Starz H, Bachter D, et al. Sentinel lymphonodectomy in nonmelanoma skin malignancies. Br J Dermatol. 2003;149(4):763–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Ahmed MM, Moore BA, Schmalbach CE. Utility of head and neck cutaneous squamous cell carcinoma sentinel node biopsy: a systematic review. Otolaryngol Head Neck Surg. 2014;150(2):180–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Durham AB, Lowe L, Malloy KM, et al. Sentinel lymph node biopsy for cutaneous squamous cell carcinoma on the head and neck. JAMA Otolaryngol Head Neck Surg. 2016;142:1171–6. Scholar
  83. 83.
    Shpitzer T, Gutman H, Barnea Y, et al. Sentinel node-guided evaluation of drainage patterns for melanoma of the helix of the ear. Melanoma Res. 2007;17(6):365–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Valsecchi ME, Silbermins D, de Rosa N, et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29(11):1479–87.PubMedCrossRefGoogle Scholar
  85. 85.
    Patel SG, Coit DC, Shaha AR, et al. Sentinel lymph nose biopsy for cutaneous head and neck melanomas. Arch Otolaryngol Head Neck Surg. 2002;128(3):285–91.PubMedCrossRefGoogle Scholar
  86. 86.
    Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224(3):255–63.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Kesmodel SB, Karakousis GC. Botbyl, et al. Mitotic rate as a predictor of sentinel lymph node biopsy in thin melanomas. Ann Surg Oncol. 2005;12(6):449–58.PubMedCrossRefGoogle Scholar
  88. 88.
    Phan GQ, Messina JL, Sondak VK, et al. Sentinel Lymph node biopsy for melanoma: indications and rationale. Cancer Control. 2009;16(3):234–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Morton DL. Overview and update of the phase III multicenter selective lymphadenectomy trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis. 2012;29(7):699–706.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Main BG, Coyle MJ, Godden A, et al. The metastatic potential of head and neck cutaneous malignant melanoma: is sentinel node biopsy useful? Br J Oral Maxillofac Surg. 2014;52(4):340–3.PubMedCrossRefGoogle Scholar
  92. 92.
    Khurana VG, Mentis DH, O’Brien CJ, et al. Parotid and neck metastases from cutaneous squamous cell carcinoma of the head and neck. Am J Surg. 1995;170(5):446–50.PubMedCrossRefGoogle Scholar
  93. 93.
    Turner SJ, Morgan GJ, Palme CE, et al. Metastatic cutaneous squamous cell carcinoma of the external ear: a high-risk cutaneous subsite. J Laryngol Otol. 2010;124(1):26–31.PubMedCrossRefGoogle Scholar
  94. 94.
    Veness MJ, Morgan GJ, Palme CE, et al. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. 2005;155(5):870–5.CrossRefGoogle Scholar
  95. 95.
    O’Hara J, Ferlito A, Takes RP. Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland – a review of current recommendations. Head Neck. 2011;33(12):1789–95.PubMedCrossRefGoogle Scholar
  96. 96.
    Medina JE. Posterolateral neck dissection. Oper Tech Otolaryngol. 2004;15:176–9.CrossRefGoogle Scholar
  97. 97.
    Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13(6):589–97.PubMedCrossRefGoogle Scholar
  98. 98.
    Mathen P, Debenham BJ, Voroney JP, et al. Clinical outcomes in stage III cutaneous melanoma treated with adjuvant radiation therapy. Int J Radiat Biol Phys. 2016;96(2S):E714.CrossRefGoogle Scholar
  99. 99.
    Soura E, Chasapi V, Strarigos AJ. Pharmacologic treatment options for advanced epithelial skin cancer. Expert Opin Pharmacother. 2015;16(10):1479–93.PubMedCrossRefGoogle Scholar
  100. 100.
    Rudnick EW, Thareja S, Cherpelis B. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. Int J Dermatol. 2016;55(3):249–58.PubMedCrossRefGoogle Scholar
  101. 101.
    Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021–6.PubMedCrossRefGoogle Scholar
  102. 102.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.PubMedCrossRefGoogle Scholar
  103. 103.
    Pectasides D, Pectasides M, Psyrri A, et al. Cisplatin-based chemotherapy for Merkel cell carcinoma of the skin. Cancer Investig. 2006;24(8):780–5.CrossRefGoogle Scholar
  104. 104.
    Davey RJ, van der Westhuizen A, Bowden NA. Metastatic melanoma treatment: combining old and new therapies. Crit Rev Oncol Hematol. 2016;98:242–53.PubMedCrossRefGoogle Scholar
  105. 105.
    Sharma A, Shah SR, Illum H, et al. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs. 2012;72(17):2207–22.PubMedCrossRefGoogle Scholar
  106. 106.
    Hiniker SM, Reddy SA, Maecker HT, et al. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int J Radiat Oncol Biol Phys. 2016;96(3):578–88.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Blair Barton
    • 1
  • Brian Moore
    • 1
  1. 1.Department of Otorhinolaryngology — Head and Neck Surgery, Ochsner Health SystemNew OrleansUSA

Personalised recommendations